Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

Celtics Live

106

101

Final

Mass. Movers

ArQule’s lead drug faces hurdle on dosing

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Joanne Rathe/Globe Staff/File 2007

ArQule is focused on developing next-generation, small-molecule cancer therapeutics.

Woburn-based ArQule Inc. and its development partner, Daiichi Sankyo Co., said that they will implement a lower dose of their treatment for hard-to-treat cases of liver cancer, Dow Jones reported. The change was recommended by a Food and Drug Administration panel following increased incidences of low white blood cell counts. The announcement is the latest hurdle for tivantinib, ArQule’s lead product candidate.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com